cagrisema phase 3 results 2025 cagrilintide semaglutide combination obesity Updates in Medicine | in Adults With or Without Diabetes โ REDEFINE 1 & 2 โข ๐ 2.4 mg + 2.4 mg once weekly โข ๐ โ20.4% weight New semaglutide and cagrilintide/semaglutide results
New semaglutide and cagrilintide semaglutide results possibilities in obesity and diabetes care Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025 Cagrilintidesemaglutide (CagriSema) as an add on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double blind, placebo controlled, multicentre, phase 3 study The Lancet Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control
Pay in 4 interest-free payments of $6.97 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 1 - Aug 6


01022-6/asset/3f55ea20-b36b-4e11-88e9-940a60e8677e/main.assets/gr2_lrg.jpg)